Ganesan Vaidyanathan

Vaidyanathan

Professor Emeritus in Radiology

Dr. Vaidyanathan is a professor in the Department of Radiology.  He is a member of the Nuclear Medicine track of the Medical Physics Graduate Program.  His research involves development of radiopharmaceuticals especially for oncologic applications.  Some of the projects he is involved in are given below.

I.          New methods of radiohalogenating antibodies and its variants 

a) Development of newer residualizing agents for the radiohalogenation of internalizing monoclonal antibodies.

b)  Development of fluorine-18 labeled residualizing agents for labeling nanobodies.

c) Pre-targeting approach via bioorthogonal chemistry for in vivo labeling of antibodies and nanobodies with 18F and 211At.

d)  Methods to label antibodies pre-conjugated with a prosthetic group of the tin precursor of residualizing agents.

e) Multimodal prosthetic groups for labeling antibodies and peptides with multiple radioisotopes.

II.         MIBG Analogs for PET imaging

Radioiodinated MIBG is used in the diagnosis of the pathophysiology of the heart as well as neuroendocrine tumors such as neuroblastoma (NB).  Design and development of newer fluorine-18 labeled MIBG analogues useful in the PET imaging of NB as well as that of myocardial diseases.

III. Noninvasive Imaging of Alkylguanine-DNA alkyltransferase (AGT) 

AGT is a DNA repair protein and is primarily responsible for drug resistance in alkylator chemotherapy. An inverse correlation has been established between the tumor AGT content and the therapeutic outcome. The amount of AGT varies from tumor to tumor and within a group of patients of similar cancer. Thus, it is important to quantify tumor AGT of individual patients before administering alkylator chemotherapy. Our goal is to develop radiolabeled agents with which AGT can be quantified in a noninvasive manner by PET or SPECT imaging. 

IV. PSMA targeting for prostate cancer therapy 

Development of At-211 labeled urea-based inhibitor of Prostate-specific membrane antigen.

Appointments and Affiliations

  • Professor Emeritus in Radiology
  • Member of the Duke Cancer Institute

Contact Information

  • Office Location: 161C Bryan Res Bldg, Durham, NC 27710
  • Office Phone: (919) 684-7811
  • Email Address: vaidy001@mc.duke.edu

Education

  • University of Kentucky, 1989
  • University of Kentucky, 1987
  • Ph.D. University of Kentucky, 1987

Courses Taught

  • MEDPHY 746: Radiopharmaceutical Chemistry

Representative Publications

  • Pruszynski, M; Koumarianou, E; Vaidyanathan, G; Revets, H; Devoogdt, N; Lahoutte, T; Zalutsky, MR, Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody., Nucl Med Biol, vol 40 no. 1 (2013), pp. 52-59 [10.1016/j.nucmedbio.2012.08.008] [abs].
  • Vaidyanathan, G; White, BJ; Affleck, DJ; Zhao, XG; Welsh, PC; McDougald, D; Choi, J; Zalutsky, MR, SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies., Bioorg Med Chem, vol 20 no. 24 (2012), pp. 6929-6939 [10.1016/j.bmc.2012.10.025] [abs].
  • Slastnikova, TA; Koumarianou, E; Rosenkranz, AA; Vaidyanathan, G; Lupanova, TN; Sobolev, AS; Zalutsky, MR, Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125I., Ejnmmi Research, vol 2 no. 1 (2012) [10.1186/2191-219X-2-59] [abs].
  • Chin, BB; Hjelemand, A; Rich, J; Song, H; Lascola, C; Storms, R; McLendon, R; Reiman, R; Greer, KL; Metzler, SD; McDougald, D; Dai, D; Vaidyanathan, G, Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression., Curr Radiopharm, vol 5 no. 1 (2012), pp. 47-58 [10.2174/1874471011205010047] [abs].
  • Vaidyanathan, G; Zalutsky, MR, Applications of 211At and 223Ra in targeted alpha-particle radiotherapy., Curr Radiopharm, vol 4 no. 4 (2011), pp. 283-294 [10.2174/1874471011104040283] [abs].
  • Vaidyanathan, G; McDougald, D; Grasfeder, L; Zalutsky, MR; Chin, B, An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine., Appl Radiat Isot, vol 69 no. 10 (2011), pp. 1401-1406 [10.1016/j.apradiso.2011.05.004] [abs].
  • Vaidyanathan, G; White, B; Affleck, DJ; McDougald, D; Zalutsky, MR, Radioiodinated O(6)-Benzylguanine derivatives containing an azido function., Nucl Med Biol, vol 38 no. 1 (2011), pp. 77-92 [10.1016/j.nucmedbio.2010.07.006] [abs].
  • Vaidyanathan, G; Zalutsky, MR, Applications of 211AT and 223RA in targeted alpha-particle radiotherapy, Current Radiopharmaceuticals, vol 4 no. 4 (2011), pp. 283-294 [abs].
  • Hens, M; Vaidyanathan, G; Zhao, X-G; Bigner, DD; Zalutsky, MR, Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands., Nucl Med Biol, vol 37 no. 7 (2010), pp. 741-750 [10.1016/j.nucmedbio.2010.04.020] [abs].
  • Kato, Y; Vaidyanathan, G; Kaneko, MK; Mishima, K; Srivastava, N; Chandramohan, V; Pegram, C; Keir, ST; Kuan, C-T; Bigner, DD; Zalutsky, MR, Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas., Nucl Med Biol, vol 37 no. 7 (2010), pp. 785-794 [10.1016/j.nucmedbio.2010.03.010] [abs].
  • Vaidyanathan, G; Affleck, DJ; Zhao, X-G; Keir, ST; Zalutsky, MR, [Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma., Curr Radiopharm, vol 3 no. 1 (2010), pp. 29-36 [10.2174/1874471011003010029] [abs].
  • Vaidyanathan, G; Song, H; Affleck, D; McDougald, DL; Storms, RW; Zalutsky, MR; Chin, BB, Targeting aldehyde dehydrogenase: a potential approach for cell labeling., Nucl Med Biol, vol 36 no. 8 (2009), pp. 919-929 [10.1016/j.nucmedbio.2009.08.001] [abs].
  • Vaidyanathan, G; Jestin, E; Olafsen, T; Wu, AM; Zalutsky, MR, Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK., Nucl Med Biol, vol 36 no. 6 (2009), pp. 671-680 [10.1016/j.nucmedbio.2009.04.002] [abs].
  • Hens, M; Vaidyanathan, G; Welsh, P; Zalutsky, MR, Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands., Nuclear Medicine and Biology, vol 36 no. 2 (2009), pp. 117-128 [10.1016/j.nucmedbio.2008.11.001] [abs].
  • Vaidyanathan, G; White, BJ; Zalutsky, MR, Propargyl 4-[F]fluorobenzoate: A Putatively More Stable Prosthetic group for the Fluorine-18 Labeling of Biomolecules via Click Chemistry., Curr Radiopharm, vol 2 no. 1 (2009), pp. 63-74 [10.2174/1874471010902010063] [abs].
  • Vaidyanathan, G, Meta-iodobenzylguanidine and analogues: chemistry and biology., The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (Aimn) [And] the International Association of Radiopharmacology (Iar), [And] Section of the Society Of.., vol 52 no. 4 (2008), pp. 351-368 [abs].
  • Rosenkranz, AA; Vaidyanathan, G; Pozzi, OR; Lunin, VG; Zalutsky, MR; Sobolev, AS, Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At., International Journal of Radiation Oncology, Biology, Physics, vol 72 no. 1 (2008), pp. 193-200 [10.1016/j.ijrobp.2008.05.055] [abs].
  • Vaidyanathan, G; Zalutsky, MR, Astatine Radiopharmaceuticals: Prospects and Problems., Curr Radiopharm, vol 1 no. 3 (2008) [10.2174/1874471010801030177] [abs].
  • Zalutsky, MR; Reardon, DA; Pozzi, OR; Vaidyanathan, G; Bigner, DD, Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies., Nuclear Medicine and Biology, vol 34 no. 7 (2007), pp. 779-785 [10.1016/j.nucmedbio.2007.03.007] [abs].
  • Vaidyanathan, G; Affleck, DJ; Alston, KL; Zhao, X-G; Hens, M; Hunter, DH; Babich, J; Zalutsky, MR, A kit method for the high level synthesis of [211At]MABG., Bioorganic & Medicinal Chemistry, vol 15 no. 10 (2007), pp. 3430-3436 [10.1016/j.bmc.2007.03.016] [abs].
  • Vaidyanathan, G; Affleck, DJ; Alston, KL; Zalutsky, MR, A tin precursor for the synthesis of no-carrier-added [*I]MIBG and [211At]MABG, Journal of Labelled Compounds & Radiopharmaceuticals, vol 50 no. 3 (2007), pp. 177-182 [10.1002/jlcr.1243] [abs].
  • Vaidyanathan, G; Zalutsky, MR, Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides., Nat Protoc, vol 2 no. 2 (2007), pp. 282-286 [10.1038/nprot.2007.20] [abs].
  • Vaidyanathan, G; Affleck, DJ; Norman, J; O'Dorisio, S; Zalutsky, MR, A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells., Bioconjugate Chemistry, vol 18 no. 6 (2007), pp. 2122-2130 [10.1021/bc700240r] [abs].
  • Shankar, S; Zalutsky, MR; Friedman, H; Vaidyanathan, G, Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine., Nuclear Medicine and Biology, vol 33 no. 3 (2006), pp. 399-407 [10.1016/j.nucmedbio.2005.12.015] [abs].
  • Shankar, S; Vaidyanathan, G; Kuan, C-T; Bigner, DD; Zalutsky, MR, Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance., Nuclear Medicine and Biology, vol 33 no. 1 (2006), pp. 101-110 [10.1016/j.nucmedbio.2005.08.004] [abs].
  • Vaidyanathan, G; Zalutsky, MR, Preparation of N-succinimidyl 3-[*I]iodobenzoate: an agent for the indirect radioiodination of proteins., Nat Protoc, vol 1 no. 2 (2006), pp. 707-713 [10.1038/nprot.2006.99] [abs].
  • Vaidyanathan, G; Zalutsky, MR, Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F., Nat Protoc, vol 1 no. 4 (2006), pp. 1655-1661 [10.1038/nprot.2006.264] [abs].
  • Vaidyanathan, G; Affleck, DJ; Schottelius, M; Wester, H; Friedman, HS; Zalutsky, MR, Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor., Bioconjugate Chemistry, vol 17 no. 1 (2006), pp. 195-203 [10.1021/bc0502560] [abs].
  • Vaidyanathan, G; Alston, KL; Bigner, DD; Zalutsky, MR, Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies., Bioconjugate Chemistry, vol 17 no. 4 (2006), pp. 1085-1092 [10.1021/bc0600766] [abs].
  • Shankar, S; Zalutsky, MR; Vaidyanathan, G, O6-3-[125I]iodobenzyl-2'-deoxyguanosine ([125I]IBdG): synthesis and evaluation of its usefulness as an agent for quantification of alkylguanine-DNA alkyltransferase (AGT)., Bioorganic & Medicinal Chemistry, vol 13 no. 12 (2005), pp. 3889-3898 [10.1016/j.bmc.2005.04.014] [abs].
  • Vaidyanathan, G; Affleck, DJ; Zalutsky, MR, No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue., Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine, vol 62 no. 3 (2005), pp. 435-440 [10.1016/j.apradiso.2004.07.001] [abs].
  • Vaidyanathan, G, Astatine-211 Labeled Radiopharmaceuticals, invited, Transactions of the American Nuclear Society, vol 91 (2004) [abs].
  • Vaidyanathan, G; Boskovitz, A; Shankar, S; Zalutsky, MR, Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers., Peptides, vol 25 no. 12 (2004), pp. 2087-2097 [10.1016/j.peptides.2004.08.018] [abs].
  • Vaidyanathan, G; Welsh, PC; Vitorello, KC; Snyder, S; Friedman, HS; Zalutsky, MR, A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells., European Journal of Nuclear Medicine and Molecular Imaging, vol 31 no. 10 (2004), pp. 1362-1370 [10.1007/s00259-004-1596-8] [abs].
  • Shankar, S; Vaidyanathan, G; Affleck, DJ; Peixoto, K; Bigner, DD; Zalutsky, MR, Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent., Nuclear Medicine and Biology, vol 31 no. 7 (2004), pp. 909-919 [10.1016/j.nucmedbio.2004.04.007] [abs].
  • Vaidyanathan, G; Affleck, DJ; Alston, KL; Welsh, P; Zalutsky, MR, Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells., Nuclear Medicine Communications, vol 25 no. 9 (2004), pp. 947-955 [10.1097/00006231-200409000-00013] [abs].
  • Boyd, M; Mairs, RJ; Keith, WN; Ross, SC; Welsh, P; Akabani, G; Owens, J; Vaidyanathan, G; Carruthers, R; Dorrens, J; Zalutsky, MR, An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects., The Journal of Gene Medicine, vol 6 no. 8 (2004), pp. 937-947 [10.1002/jgm.578] [abs].
  • Vaidyanathan, G; Shankar, S; Affleck, DJ; Alston, K; Norman, J; Welsh, P; LeGrand, H; Zalutsky, MR, Meta-iodobenzylguanidine derivatives containing a second guanidine moiety., Bioorganic & Medicinal Chemistry, vol 12 no. 7 (2004), pp. 1649-1656 [10.1016/j.bmc.2004.01.026] [abs].
  • Vaidyanathan, G; Affleck, DJ; Norman, J; Welsh, P; Liu, W; Johnson, SP; Friedman, HS; Zalutsky, MR, O6-3-[131I]iodobenzylguanine: improved synthesis and further evaluation of a potential agent for imaging of alkylguanine-DNA alkyltransferase., Bioconjugate Chemistry, vol 15 no. 2 (2004), pp. 402-408 [10.1021/bc0341977] [abs].
  • Vaidyanathan, G; Zalutsky, MR, Imaging drug resistance with radiolabeled molecules., Current Pharmaceutical Design, vol 10 no. 24 (2004), pp. 2965-2979 [10.2174/1381612043383449] [abs].
  • Vaidyanathan, G; Friedman, HS; Affleck, DJ; Schottelius, M; Wester, H-J; Zalutsky, MR, Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts., Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol 9 no. 5 (2003), pp. 1868-1876 [abs].
  • Vaidyanathan, G; Affleck, DJ; Bigner, DD; Zalutsky, MR, N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At., Nuclear Medicine and Biology, vol 30 no. 4 (2003), pp. 351-359 [10.1016/s0969-8051(03)00005-2] [abs].
  • Shankar, S; Vaidyanathan, G; Affleck, D; Welsh, PC; Zalutsky, MR, N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs., Bioconjugate Chemistry, vol 14 no. 2 (2003), pp. 331-341 [10.1021/bc025636p] [abs].
  • Vaidyanathan, G; Affleck, DJ; Bigner, DD; Zalutsky, MR, Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate., Nuclear Medicine and Biology, vol 29 no. 1 (2002), pp. 1-11 [10.1016/s0969-8051(01)00277-3] [abs].
  • Vaidyanathan, G; Shankar, S; Affleck, DJ; Welsh, PC; Slade, SK; Zalutsky, MR, Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues., Bioconjugate Chemistry, vol 12 no. 5 (2001), pp. 798-806 [10.1021/bc010032r] [abs].
  • Vaidyanathan, G; Affleck, DJ; Li, J; Welsh, P; Zalutsky, MR, A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB)., Bioconjugate Chemistry, vol 12 no. 3 (2001), pp. 428-438 [10.1021/bc0001490] [abs].
  • Vaidyanathan, G; Shankar, S; Zalutsky, MR, Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues., Bioconjugate Chemistry, vol 12 no. 5 (2001), pp. 786-797 [10.1021/bc010031z] [abs].
  • Zalutsky, MR; Vaidyanathan, G, Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy., Current Pharmaceutical Design, vol 6 no. 14 (2000), pp. 1433-1455 [10.2174/1381612003399275] [abs].
  • Vaidyanathan, G; Affleck, D; Welsh, P; Srinivasan, A; Schmidt, M; Zalutsky, MR, Radioiodination and astatination of octreotide by conjugation labeling., Nuclear Medicine and Biology, vol 27 no. 4 (2000), pp. 329-337 [10.1016/s0969-8051(00)00098-6] [abs].
  • Vaidyanathan, G; Affleck, DJ; Cavazos, CM; Johnson, SP; Shankar, S; Friedman, HS; Colvin, MO; Zalutsky, MR, Radiolabeled guanine derivatives for the in vivo mapping of O(6)-alkylguanine-DNA alkyltransferase: 6-(4-[(18)F]Fluoro-benzyloxy)-9H-purin-2-ylamine and 6-(3-[(131)I]Iodo-benzyloxy)-9H-purin-2-ylamine., Bioconjugate Chemistry, vol 11 no. 6 (2000), pp. 868-875 [10.1021/bc0000435] [abs].
  • Vaidyanathan, G; Srinivasan, A; Affleck, DJ; Welsh, PC; Slade, SK; Schmidt, MA; Zalutsky, MR, Octreotide analogues labeled with radioiodine and astatine-211, Journal of Labelled Compounds & Radiopharmaceuticals, vol 42 no. SUPPL. 1 (1999) [abs].
  • Walicka, MA; Vaidyanathan, G; Zalutsky, MR; Adelstein, SJ; Kassis, AI, Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211., Radiation Research, vol 150 no. 3 (1998), pp. 263-268 [abs].
  • Vaidyanathan, G; Zalutsky, MR, Preparation of 5-[131I]iodo- and 5-[211At]astato-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil by a halodestannylation reaction., Nuclear Medicine and Biology, vol 25 no. 5 (1998), pp. 487-496 [10.1016/s0969-8051(98)00004-3] [abs].
  • Cunningham, SH; Mairs, RJ; Wheldon, TE; Welsh, PC; Vaidyanathan, G; Zalutsky, MR, Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions., British Journal of Cancer, vol 77 no. 12 (1998), pp. 2061-2068 [10.1038/bjc.1998.348] [abs].
  • DeGrado, TR; Zalutsky, MR; Coleman, RE; Vaidyanathan, G, Effects of specific activity on meta-[(131)I]iodobenzylguanidine kinetics in isolated rat heart., Nuclear Medicine and Biology, vol 25 no. 1 (1998), pp. 59-64 [10.1016/s0969-8051(97)00158-3] [abs].
  • Vaidyanathan, G; Zalutsky, MR; DeGrado, TR, Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine., Bioconjugate Chemistry, vol 9 no. 6 (1998), pp. 758-764 [10.1021/bc980037x] [abs].
  • Larsen, RH; Vaidyanathan, G; Zalutsky, MR, Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells., International Journal of Radiation Biology, vol 72 no. 1 (1997), pp. 79-90 [10.1080/095530097143563] [abs].
  • Vaidyanathan, G; Zalutsky, MR, Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue., Nuclear Medicine and Biology, vol 24 no. 2 (1997), pp. 171-178 [10.1016/s0969-8051(96)00211-9] [abs].
  • Vaidyanathan, G; Zhao, XG; Strickland, DK; Zalutsky, MR, No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog., Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol 38 no. 2 (1997), pp. 330-334 [abs].
  • Vaidyanathan, G; Affleck, DJ; Zalutsky, MR, Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate., Bioconjugate Chemistry, vol 8 no. 5 (1997), pp. 724-729 [10.1021/bc9700502] [abs].
  • Vaidyanathan, G; Zhao, XG; Larsen, RH; Zalutsky, MR, 3-[211At]astato-4-fluorobenzylguanidine: A potential therapeutic agent with prolonged retention by neuroblastoma cells, British Journal of Cancer, vol 76 no. 2 (1997), pp. 226-233 [abs].
  • Vaidyanathan, G; Zalutsky, MR, Targeted therapy using alpha emitters., Physics in Medicine and Biology, vol 41 no. 10 (1996), pp. 1915-1931 [10.1088/0031-9155/41/10/005] [abs].
  • Vaidyanathan, G; Friedman, HS; Keir, ST; Zalutsky, MR, Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model., Nuclear Medicine and Biology, vol 23 no. 6 (1996), pp. 851-856 [10.1016/0969-8051(96)00115-1] [abs].
  • Vaidyanathan, G; Friedman, HS; Keir, ST; Zalutsky, MR, Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity., British Journal of Cancer, vol 73 no. 10 (1996), pp. 1171-1177 [10.1038/bjc.1996.226] [abs].
  • Vaidyanathan, G; Larsen, RH; Zalutsky, MR, 5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation., Cancer Research, vol 56 no. 6 (1996), pp. 1204-1209 [abs].
  • Vaidyanathan, G; Affleck, DJ; Zalutsky, MR, No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine., Bioconjugate Chemistry, vol 7 no. 1 (1996), pp. 102-107 [10.1021/bc950078i] [abs].
  • Reist, CJ; Archer, GE; Kurpad, SN; Wikstrand, CJ; Vaidyanathan, G; Willingham, MC; Moscatello, DK; Wong, AJ; Bigner, DD; Zalutsky, MR, Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts., Cancer Research, vol 55 no. 19 (1995), pp. 4375-4382 [abs].
  • Vaidyanathan, G; Zalutsky, MR, Fluorine-18 labeled chemotactic peptides: a potential approach for the PET imaging of bacterial infection., Nuclear Medicine and Biology, vol 22 no. 6 (1995), pp. 759-764 [10.1016/0969-8051(95)00028-v] [abs].
  • Vaidyanathan, G; Affleck, DJ; Zalutsky, MR, Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG., Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol 36 no. 4 (1995), pp. 644-650 [abs].
  • Degrado, TR; Zalutsky, MR; Vaidyanathan, G, Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart., Nuclear Medicine and Biology, vol 22 no. 1 (1995), pp. 1-12 [10.1016/0969-8051(94)00084-w] [abs].
  • Vaidyanathan, G; Zalutsky, MR, No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation., Nuclear Medicine and Biology, vol 22 no. 1 (1995), pp. 61-64 [10.1016/0969-8051(94)00078-x] [abs].
  • Johnson, EL; Turkington, TG; Jaszczak, RJ; Gilland, DR; Vaidyanathan, G; Greer, KL; Coleman, RE; Zalutsky, MR, Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models., Nuclear Medicine and Biology, vol 22 no. 1 (1995), pp. 45-54 [10.1016/0969-8051(94)00077-w] [abs].
  • Mairs, RJ; Russell, J; Cunningham, S; O'Donoghue, JA; Gaze, MN; Owens, J; Vaidyanathan, G; Zalutsky, MR, Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma., European Journal of Cancer, vol 31A no. 4 (1995), pp. 576-581 [10.1016/0959-8049(95)00052-k] [abs].
  • Strickland, DK; Vaidyanathan, G; Friedman, HS; Zalutsky, MR, Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines., Journal of Neuro Oncology, vol 25 no. 1 (1995), pp. 9-17 [10.1007/BF01054718] [abs].
  • Strickland, DK; Vaidyanathan, G; Zalutsky, MR, Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells., Cancer Research, vol 54 no. 20 (1994), pp. 5414-5419 [abs].
  • Vaidyanathan, G; Affleck, DJ; Zalutsky, MR, (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography., Journal of Medicinal Chemistry, vol 37 no. 21 (1994), pp. 3655-3662 [10.1021/jm00047a022] [abs].
  • Page, RL; Garg, PK; Vaidyanathan, G; Zalutsky, MR, Preclinical evaluation and PET imaging of 18F-labeled Mel-14 F(ab')2 fragment in normal dogs., Nuclear Medicine and Biology, vol 21 no. 7 (1994), pp. 911-919 [10.1016/0969-8051(94)90079-5] [abs].
  • Vaidyanathan, G; Strickland, DK; Zalutsky, MR, Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent., International Journal of Cancer, vol 57 no. 6 (1994), pp. 908-913 [10.1002/ijc.2910570622] [abs].
  • Mairs, RJ; Gaze, MN; Watson, DG; Skellern, GG; Constable, P; McKellar, K; Owens, J; Vaidyanathan, G; Zalutsky, MR, Carrier-free 131I-meta-iodobenzylguanidine: comparison of production from meta-diazobenzylguanidine and from meta-trimethylsilylbenzylguanidine., Nuclear Medicine Communications, vol 15 no. 4 (1994), pp. 268-274 [10.1097/00006231-199404000-00157] [abs].
  • Vaidyanathan, G; Affleck, D; Zalutsky, MR, Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments., Nuclear Medicine and Biology, vol 21 no. 1 (1994), pp. 105-110 [10.1016/0969-8051(94)90136-8] [abs].
  • Vaidyanathan, G; Zalutsky, MR, Improved synthesis of N-succinimidyl 4-[18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment., Bioconjugate Chemistry, vol 5 no. 4 (1994), pp. 352-356 [10.1021/bc00028a012] [abs].
  • Gaze, MN; Mairs, RJ; Vaidyanathan, G; Zalutsky, MR, Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma., Progress in Clinical and Biological Research, vol 385 (1994), pp. 347-353 [abs].
  • Turkington, TG; Zalutsky, MR; Jaszczak, RJ; Garg, PK; Vaidyanathan, G; Coleman, RE, Measuring astatine-211 distributions with SPECT., Physics in Medicine and Biology, vol 38 no. 8 (1993), pp. 1121-1130 [10.1088/0031-9155/38/8/010] [abs].
  • Vaidyanathan, G; Zalutsky, MR, No-carrier-added synthesis of meta-[131I]iodobenzylguanidine., Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine, vol 44 no. 3 (1993), pp. 621-628 [10.1016/0969-8043(93)90179-e] [abs].
  • Vaidyanathan, G; Affleck, DJ; Zalutsky, MR, Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate., Bioconjugate Chemistry, vol 4 no. 1 (1993), pp. 78-84 [10.1021/bc00019a011] [abs].
  • Vaidyanathan, G; Bigner, DD; Zalutsky, MR, Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography., Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol 33 no. 8 (1992), pp. 1535-1541 [abs].
  • Vaidyanathan, G; Zalutsky, MR, Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate., International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology, vol 19 no. 3 (1992), pp. 275-281 [10.1016/0883-2897(92)90111-b] [abs].
  • Vaidyanathan, G; Jay, M; Bera, RK; Mayer, PR; Brazzell, RK, Scintigraphic evaluation of the ocular disposition of 18F-imirestat in rabbits., Pharm Res, vol 7 no. 11 (1990), pp. 1198-1200 [10.1023/a:1015952930541] [abs].
  • Vaidyanathan, G; Zalutsky, MR, Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates., Bioconjugate Chemistry, vol 1 no. 6 (1990), pp. 387-393 [10.1021/bc00006a004] [abs].
  • Vaidyanathan, G; Zalutsky, MR, Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents., Bioconjugate Chemistry, vol 1 no. 4 (1990), pp. 269-273 [10.1021/bc00004a007] [abs].
  • Vaidyanathan, G; Wilson, JW, Reaction of Cyclopropanamines with Hypochlorite, The Journal of Organic Chemistry, vol 54 no. 8 (1989), pp. 1815-1820 [10.1021/jo00269a014] [abs].
  • Vaidyanathan, G; Wilson, JW, Decarboxylation of 1-Aminocyclopropanecarboxylic Acid and Its Derivatives, The Journal of Organic Chemistry, vol 54 no. 8 (1989), pp. 1810-1815 [10.1021/jo00269a013] [abs].